Action Point Financial Planning’s Intellia Therapeutics NTLA Stock Holding History

Action Point Financial Planning’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85	Buy	+5	New	+$70	﹤0.01%	2734

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Action Point Financial Planning's NTLA Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 5 shares worth $85. The stake represents ﹤0.01% of the portfolio and ranks #2734 among its holdings.

326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

Action Point Financial Planning held 5 shares of Intellia Therapeutics worth $85 as of Q2 2026.
Intellia Therapeutics was a new Action Point Financial Planning position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2734 holding.
326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.